Requests that the FDA take administrative action to improve the safety of discontinuing Cymbalta (duloxetine) and generic equivalents by requiring standardized tapering formulations, updated labeling, and patient access protections | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2026-P-1831

Requests that the FDA take administrative action to improve the safety of discontinuing Cymbalta (duloxetine) and generic equivalents by requiring standardized tapering formulations, updated labeling, and patient access protections

Documents

Comments

Description

Open

Key Dates

Comment Period OpensFeb 19, 2026

Documents

Type	Title	Posted	Comments	Status
Other	SSRI listening session minutes_3-24-26	Apr 24, 2026	--

Comment Statistics

Total Comments

Keywords

CDER

Citizen Petition

Requests that the FDA take administrative

action to improve the safety of discontinuing

Cymbalta (duloxetine) and generic equivalents

by requiring standardized tapering formulations,

updated labeling, and patient access protections

Open

Data from Regulations.gov